JP2006525811A - Ｒｎａ干渉の方法と組成物 - Google Patents

Ｒｎａ干渉の方法と組成物 Download PDF

Info

Publication number
JP2006525811A
JP2006525811A JP2006514886A JP2006514886A JP2006525811A JP 2006525811 A JP2006525811 A JP 2006525811A JP 2006514886 A JP2006514886 A JP 2006514886A JP 2006514886 A JP2006514886 A JP 2006514886A JP 2006525811 A JP2006525811 A JP 2006525811A
Authority
JP
Japan
Prior art keywords
sirna
genes
sequence
gene
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006514886A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006525811A5 (enExample
Inventor
ジャクソン，エイミー，エル．
バーツ，スティーヴン，アール．
バーチャード，ジュリア
シェルター，ジャネル，エム．
リンズリー，ピーター，エス．
Original Assignee
ロゼッタ インファーマティクス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ロゼッタ インファーマティクス エルエルシー filed Critical ロゼッタ インファーマティクス エルエルシー
Publication of JP2006525811A publication Critical patent/JP2006525811A/ja
Publication of JP2006525811A5 publication Critical patent/JP2006525811A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2006514886A 2003-05-16 2004-05-17 Ｒｎａ干渉の方法と組成物 Pending JP2006525811A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47139203P 2003-05-16 2003-05-16
US51522303P 2003-10-27 2003-10-27
PCT/US2004/015439 WO2005018534A2 (en) 2003-05-16 2004-05-17 Methods and compositions for rna interference

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010202235A Division JP2011004763A (ja) 2003-05-16 2010-09-09 Ｒｎａ干渉の方法と組成物

Publications (2)

Publication Number Publication Date
JP2006525811A true JP2006525811A (ja) 2006-11-16
JP2006525811A5 JP2006525811A5 (enExample) 2007-07-05

Family

ID=34221197

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006514886A Pending JP2006525811A (ja) 2003-05-16 2004-05-17 Ｒｎａ干渉の方法と組成物
JP2010202235A Pending JP2011004763A (ja) 2003-05-16 2010-09-09 Ｒｎａ干渉の方法と組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010202235A Pending JP2011004763A (ja) 2003-05-16 2010-09-09 Ｒｎａ干渉の方法と組成物

Country Status (5)

Country Link
US (1) US8609830B2 (enExample)
EP (1) EP1628993A4 (enExample)
JP (2) JP2006525811A (enExample)
CA (1) CA2525619A1 (enExample)
WO (1) WO2005018534A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219565A1 (en) 2002-10-21 2004-11-04 Sakari Kauppinen Oligonucleotides useful for detecting and analyzing nucleic acids of interest
US8447526B2 (en) 2005-05-23 2013-05-21 Microsoft Corporation Methods and computer systems for analyzing high-throughput assays
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2008137862A2 (en) * 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Methods of using mir34 as a biomarker for tp53 functional status
IN2009KN04568A (enExample) 2007-06-01 2015-08-28 Univ Princeton
KR101840618B1 (ko) * 2008-12-04 2018-03-20 큐알엔에이, 인크. 종양 억제 유전자에 대한 천연 안티센스 전사체의 억제에 의해 종양 억제 유전자 관련된 질환의 치료
US20130131148A1 (en) * 2010-04-12 2013-05-23 Noam Shomron Micro-rna for cancer diagnosis, prognosis and therapy
DE102011009470A1 (de) * 2011-01-21 2012-08-09 Friedrich-Schiller-Universität Jena Biologisch wirksame Nukleotid-Moleküle zur gezielten Abtötung von Zellen, Verwendung derselben sowie Applikationskit
WO2012143427A1 (en) * 2011-04-19 2012-10-26 Santaris Pharma A/S Anti polyomavirus compounds
EP3554535A4 (en) 2016-12-14 2020-10-21 Janssen Biotech, Inc. PD-L1 BINDING FIBRONECTIN TYPE III DOMAINS
EP3554561B1 (en) 2016-12-14 2023-06-28 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CN110225770B (zh) 2016-12-14 2022-04-26 杨森生物科技公司 结合cd8a的纤连蛋白iii型结构域
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
JP2022551204A (ja) 2019-10-14 2022-12-07 アロ・バイオセラピューティクス・カンパニー Ｃｄ７１結合フィブロネクチンｉｉｉ型ドメイン
MX2023012128A (es) 2021-04-14 2024-01-11 Aro Biotherapeutics Company Dominios tipo iii de la fibronectina que se unen a cd71.
KR20240031947A (ko) 2021-04-14 2024-03-08 에이알오 바이오테라퓨틱스 컴패니 Fn3 도메인-시르나 접합체 및 이의 용도

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US6040138A (en) 1995-09-15 2000-03-21 Affymetrix, Inc. Expression monitoring by hybridization to high density oligonucleotide arrays
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
PT969102E (pt) 1991-09-24 2008-03-25 Keygene Nv Iniciadores, grupos e conjuntos de fragmentos de restrição usados na amplificação selectiva de fragmentos de restrição
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6165709A (en) 1997-02-28 2000-12-26 Fred Hutchinson Cancer Research Center Methods for drug target screening
US6028189A (en) 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
WO1998041531A2 (en) 1997-03-20 1998-09-24 University Of Washington Solvent for biopolymer synthesis, solvent microdroplets and methods of use
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6217002B1 (en) * 1998-01-13 2001-04-17 Terry C. Shafer Valve assembly having floating retainer rings
US5965352A (en) 1998-05-08 1999-10-12 Rosetta Inpharmatics, Inc. Methods for identifying pathways of drug action
US6324479B1 (en) 1998-05-08 2001-11-27 Rosetta Impharmatics, Inc. Methods of determining protein activity levels using gene expression profiles
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6132969A (en) 1998-06-19 2000-10-17 Rosetta Inpharmatics, Inc. Methods for testing biological network models
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
US6950752B1 (en) 1998-10-27 2005-09-27 Rosetta Inpharmatics Llc Methods for removing artifact from biological profiles
US6801859B1 (en) 1998-12-23 2004-10-05 Rosetta Inpharmatics Llc Methods of characterizing drug activities using consensus profiles
US6351712B1 (en) 1998-12-28 2002-02-26 Rosetta Inpharmatics, Inc. Statistical combining of cell expression profiles
US6132997A (en) 1999-05-28 2000-10-17 Agilent Technologies Method for linear mRNA amplification
US20020016216A1 (en) 1999-06-08 2002-02-07 Kenji Kobayashi Golf club
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
WO2002018464A2 (en) 2000-08-29 2002-03-07 Mallinckrodt Baker Inc. Functionalized polymeric media for separation of analytes
WO2002044399A2 (en) 2000-11-28 2002-06-06 Rosetta Inpharmatics, Inc. In vitro transcription method for rna amplification
CZ302719B6 (cs) * 2000-12-01 2011-09-21 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití
US20020182590A1 (en) * 2001-05-25 2002-12-05 Vanderbilt University Determining protein function in cell culture using RNA interference
CA2921821A1 (en) 2001-07-12 2003-01-23 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
US7418351B2 (en) 2002-01-31 2008-08-26 Rosetta Inpharmatics Llc Methods for analysis of measurement errors in measured signals
US20040248299A1 (en) * 2002-12-27 2004-12-09 Sumedha Jayasena RNA interference
US7996155B2 (en) 2003-01-22 2011-08-09 Microsoft Corporation ANOVA method for data analysis
EP1692262B1 (en) 2003-10-27 2018-08-15 Merck Sharp & Dohme Corp. Method of designing sirnas for gene silencing

Also Published As

Publication number Publication date
WO2005018534A2 (en) 2005-03-03
US8609830B2 (en) 2013-12-17
CA2525619A1 (en) 2005-03-03
JP2011004763A (ja) 2011-01-13
EP1628993A2 (en) 2006-03-01
WO2005018534A3 (en) 2005-12-08
US20070149468A1 (en) 2007-06-28
EP1628993A4 (en) 2010-04-07

Similar Documents

Publication Publication Date Title
JP2011004763A (ja) Ｒｎａ干渉の方法と組成物
JP4790619B2 (ja) 遺伝子サイレンシングのためのｓｉＲＮＡを設計する方法
Guarnieri et al. MicroRNAs: a new class of gene regulators
Chung et al. Endogenous RNA interference provides a somatic defense against Drosophila transposons
Ichihara et al. Thermodynamic instability of siRNA duplex is a prerequisite for dependable prediction of siRNA activities
Elkon et al. Dissection of a DNA-damage-induced transcriptional network using a combination of microarrays, RNA interference and computational promoter analysis
Rau et al. Systems genetics approach identifies gene pathways and Adamts2 as drivers of isoproterenol-induced cardiac hypertrophy and cardiomyopathy in mice
US20120171686A1 (en) Methods for the identification of microrna and their applications in research and human health
CN1890370A (zh) RNAi潜能的预测方法
US7996155B2 (en) ANOVA method for data analysis
US20140088937A1 (en) Methods of Predicting The Probability of Modulation of Transcript Levels By RNAI Compounds
WO2009042115A2 (en) Methods of designing short hairpin rnas (shrnas) for gene silencing
JP2007532136A (ja) 作用因子に対する生細胞の応答を媒介する遺伝子を同定する方法
Hashemikhabir Dissecting Protein-RNA Interaction Network in Human Genome
WO2004068136A1 (en) Improved anova method for data analysis
ANNOTATION to annotate the sequence. Bioinformatic analysis can
HK1101702A (en) Rnai potency prediction method
AU2013200586A1 (en) Methods for the identification of microRNA and their applications in research and human health

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070516

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070516

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100309

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100608

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100615

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100706

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100909

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110621